Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis AG (NVS) CEO Vas Narasimhan on Q2 2022 Results - Earnings Call Transcript
01:47pm, Tuesday, 19'th Jul 2022
Novartis AG (NYSE:NVS ) Q2 2022 Results Conference Call July 19, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
12:23pm, Tuesday, 19'th Jul 2022
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
IBM And 20 Stocks Moving Premarket
10:39am, Tuesday, 19'th Jul 2022 Benzinga
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) rose 32.1% to $1.40 in pre-market trading after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raise
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
06:08am, Tuesday, 19'th Jul 2022
Novartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the consensus of $1.52. Net sales were $12.78 billion, down 1% Y/Y or up 5% at constant cur
Novartis no longer expects earnings decline at under-review Sandoz unit
01:20am, Tuesday, 19'th Jul 2022
Swiss drugmaker Novartis said earnings at its Sandoz unit, the maker of cheap generic drugs that might be put up for sale, would likely be flat this year, no longer expecting a decline, and added the
With Brighter Outlook, Generics Could Be Ripe for Investment
04:26pm, Monday, 18'th Jul 2022
Of the top 10 generic drugmakers in 2021, only one scored an increase in share price during the past year. It was Sun Pharmaceutical Industries Ltd.
Could Pliant Therapeutics Stock Double Your Money?
03:30pm, Monday, 18'th Jul 2022 The Motley Fool
Wall Street thinks this red-hot biotech stock has a lot more room to run.
2 Top Biotech Stocks to Buy Right Now
03:15pm, Friday, 15'th Jul 2022 The Motley Fool
Each of these companies has exceptional existing drug portfolios and drug pipelines.
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
06:53pm, Thursday, 14'th Jul 2022 Benzinga
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell c
Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?
03:16pm, Monday, 11'th Jul 2022 Zacks Investment Research
Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.
Beat The Bear With 3 Tools: Dividends, Dividends And Dividends
12:28pm, Sunday, 10'th Jul 2022 Investing.com
9 High-Yield Dividend Aristocrats You Haven't Considered But Definitely Should
01:45pm, Saturday, 09'th Jul 2022 Seeking Alpha
Dividend aristocrats are some of the most time-tested dividend blue-chips in America. But the world is full of top quality and very dependable dividend growth powerhouses.
Novartis debuted its first integrated sustainability and finance report this year — more companies are likely to follow suit
03:09pm, Wednesday, 06'th Jul 2022
The global pharmaceutical company, Novartis, released its first-ever integrated social impact report. The report connects sustainability goals and business objectives.
Novartis: A Safe Bear Market Value Buy Now Yielding 4%
08:15am, Wednesday, 06'th Jul 2022
Novartis is a leading global pharmaceutical company with a solid portfolio of drugs, a strong pipeline, and a focus on shareholder returns. It maintains strong profitability, giving it sufficient buff
Novartis Is Awakening From Lethargy
06:04am, Wednesday, 06'th Jul 2022
The street consensus anticipates 7.71% net profit CAGR over the next 5 years. Targeted acquisition, a likely spinoff of Sandoz and $15B share buyback underscore the commitment of investing in the core
